- Home
- SSTK vs CVAC Comparison
SSTK vs CVAC Comparison
Compare SSTK & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTK
- CVAC
- Stock Information
- Founded
- SSTK 2003
- CVAC 2000
- Country
- SSTK United States
- CVAC Germany
- Employees
- SSTK N/A
- CVAC N/A
- Industry
- SSTK EDP Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- SSTK Technology
- CVAC Health Care
- Exchange
- SSTK Nasdaq
- CVAC Nasdaq
- Market Cap
- SSTK 644.4M
- CVAC 764.4M
- IPO Year
- SSTK 2012
- CVAC 2020
- Fundamental
- Price
- SSTK $18.45
- CVAC $5.41
- Analyst Decision
- SSTK Buy
- CVAC Buy
- Analyst Count
- SSTK 4
- CVAC 3
- Target Price
- SSTK $43.67
- CVAC $9.00
- AVG Volume (30 Days)
- SSTK 274.5K
- CVAC 2.1M
- Earning Date
- SSTK 08-05-2025
- CVAC 08-14-2025
- Dividend Yield
- SSTK 7.12%
- CVAC N/A
- EPS Growth
- SSTK N/A
- CVAC N/A
- EPS
- SSTK 1.09
- CVAC 0.87
- Revenue
- SSTK $963,567,000.00
- CVAC $566,039,775.00
- Revenue This Year
- SSTK $11.31
- CVAC N/A
- Revenue Next Year
- SSTK $2.40
- CVAC $24.04
- P/E Ratio
- SSTK $17.09
- CVAC $6.28
- Revenue Growth
- SSTK 10.30
- CVAC 787.60
- 52 Week Low
- SSTK $14.35
- CVAC $2.37
- 52 Week High
- SSTK $46.10
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- SSTK 51.11
- CVAC 66.80
- Support Level
- SSTK $18.43
- CVAC $5.30
- Resistance Level
- SSTK $19.05
- CVAC $5.58
- Average True Range (ATR)
- SSTK 0.76
- CVAC 0.15
- MACD
- SSTK 0.01
- CVAC 0.00
- Stochastic Oscillator
- SSTK 41.27
- CVAC 82.76
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.